Project Grant R43HL182659
Award Date 9/1/26
Completion Date 7/31/27
Dollars Obligated $356K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92126, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Greenstone Biosciences, Inc. $625,968 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct small-molecule drug discovery for cardiac fibrosis associated with Duchenne muscular dystrophy using artificial intelligence, machine learning, and induced pluripotent stem cell-derived organoids. The R61 phase will perform unbiased proteomics on DMD iPSC-derived cardiomyocytes and cardiac fibroblasts to...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $235,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac complications of dystrophin deficiency in female carriers of Duchenne muscular dystrophy. The research will examine how mosaic expression of dystrophin affects cardiomyocytes differentiated from human induced pluripotent stem cells of female carriers. The work will compare functional...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ikaika Therapeutics Inc. $995,938 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund preclinical development of anti-LTBP4 monoclonal antibodies for treating neuromuscular diseases. The project develops second-generation anti-LTBP4 antibodies targeting the hinge region of latent TGF-binding protein 4, which regulates pathological TGF-β activation...
- The National Heart, Lung, and Blood Institute awarded the University of Miami $381,511 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate gasdermin D (GSDMD) as a therapeutic target in neonatal hyperoxia-induced vascular dysfunction. The project addresses the long-term cardiovascular morbidities—including hypertension, ischemic heart disease, and heart failure—that affect preterm-born survivors exposed to supraphysiological oxygen levels during...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Heart, Lung, and Blood Institute awarded the University of Miami $345,375 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of gasdermin-D in neonatal hyperoxia-induced vascular remodeling and cardiac dysfunction. The project grant (R03HL183267) runs through February 28, 2028, with work performed in Miami, Florida. The research targets mechanisms by which oxygen therapy in preterm infants—necessary to ensure adequate oxygen...
- This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...